Literature DB >> 23093773

Targeted deletion of Vegfa in adult mice induces vision loss.

Toshihide Kurihara1, Peter D Westenskow, Stephen Bravo, Edith Aguilar, Martin Friedlander.   

Abstract

Current therapies directed at controlling vascular abnormalities in cancers and neovascular eye diseases target VEGF and can slow the progression of these diseases. While the critical role of VEGF in development has been well described, the function of locally synthesized VEGF in the adult eye is incompletely understood. Here, we show that conditionally knocking out Vegfa in adult mouse retinal pigmented epithelial (RPE) cells, which regulate retinal homeostasis, rapidly leads to vision loss and ablation of the choriocapillaris, the major blood supply for the outer retina and photoreceptor cells. This deletion also caused rapid dysfunction of cone photoreceptors, the cells responsible for fine visual acuity and color vision. Furthermore, Vegfa deletion showed significant downregulation of multiple angiogenic genes in both physiological and pathological states, whereas the deletion of the upstream regulatory transcriptional factors HIFs did not affect the physiological expressions of angiogenic genes. These results suggest that endogenous VEGF provides critical trophic support necessary for retinal function. Targeting factors upstream of VEGF, such as HIFs, may be therapeutically advantageous compared with more potent and selective VEGF antagonists, which may have more off-target inhibitory trophic effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23093773      PMCID: PMC3484459          DOI: 10.1172/JCI65157

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.

Authors:  Philip J Rosenfeld; Howard Shapiro; Lisa Tuomi; Mary Webster; Julee Elledge; Barbara Blodi
Journal:  Ophthalmology       Date:  2011-03       Impact factor: 12.079

Review 2.  Therapeutic targets in age-related macular disease.

Authors:  Alan C Bird
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

Review 3.  Oxygen sensing, homeostasis, and disease.

Authors:  Gregg L Semenza
Journal:  N Engl J Med       Date:  2011-08-11       Impact factor: 91.245

4.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.

Authors:  H E Ryan; M Poloni; W McNulty; D Elson; M Gassmann; J M Arbeit; R S Johnson
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

5.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

6.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.

Authors:  Michael I Dorrell; Edith Aguilar; Ruth Jacobson; Oscar Yanes; Ray Gariano; John Heckenlively; Eyal Banin; G Anthony Ramirez; Mehdi Gasmi; Alan Bird; Gary Siuzdak; Martin Friedlander
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

7.  Temporal requirement of RPE-derived VEGF in the development of choroidal vasculature.

Authors:  Yun-Zheng Le; Yanyan Bai; Meili Zhu; Lixin Zheng
Journal:  J Neurochem       Date:  2010-01-08       Impact factor: 5.372

8.  Astrocyte pVHL and HIF-α isoforms are required for embryonic-to-adult vascular transition in the eye.

Authors:  Toshihide Kurihara; Peter D Westenskow; Tim U Krohne; Edith Aguilar; Randall S Johnson; Martin Friedlander
Journal:  J Cell Biol       Date:  2011-11-14       Impact factor: 10.539

9.  Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1.

Authors:  Marija Cvetanovic; Jay M Patel; Hugo H Marti; Ameet R Kini; Puneet Opal
Journal:  Nat Med       Date:  2011-10-16       Impact factor: 53.440

10.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

View more
  156 in total

Review 1.  Plasma membrane protein polarity and trafficking in RPE cells: past, present and future.

Authors:  Guillermo L Lehmann; Ignacio Benedicto; Nancy J Philp; Enrique Rodriguez-Boulan
Journal:  Exp Eye Res       Date:  2014-09       Impact factor: 3.467

Review 2.  Imaging of the parafoveal capillary network in diabetes.

Authors:  Gábor György Deák; Ursula Schmidt-Erfurth
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

Review 3.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Angiographic features of transgenic mice with increased expression of human serine protease HTRA1 in retinal pigment epithelium.

Authors:  Sandeep Kumar; Zachary Berriochoa; Balamurali K Ambati; Yingbin Fu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

5.  Ritonavir inhibits HIF-1α-mediated VEGF expression in retinal pigment epithelial cells in vitro.

Authors:  R K Vadlapatla; A D Vadlapudi; D Pal; M Mukherji; A K Mitra
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

6.  Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration.

Authors:  Xiaowu Gu; Steven J Fliesler; You-Yang Zhao; William B Stallcup; Alex W Cohen; Michael H Elliott
Journal:  Am J Pathol       Date:  2013-12-08       Impact factor: 4.307

Review 7.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

8.  Turning a blind eye to anti-VEGF toxicities.

Authors:  Susan E Quaggin
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

9.  Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

Authors:  Gabriela D'Amico; Emilia A Korhonen; Andrey Anisimov; Georgia Zarkada; Tanja Holopainen; René Hägerling; Friedemann Kiefer; Lauri Eklund; Raija Sormunen; Harri Elamaa; Rolf A Brekken; Ralf H Adams; Gou Young Koh; Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 10.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.